Onconova Therapeutics, Inc. filed its 10-K on Mar 30, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6456 USD | 0.00% | +0.72% | -13.41% |
05-07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
04-04 | North American Morning Briefing : Focus Turns to -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.41% | 13.61M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- TRAW Stock
- News Traws Pharma, Inc.
- Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt